Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 25(4)2024 Feb 07.
Article in English | MEDLINE | ID: mdl-38396694

ABSTRACT

Universal diagnostic criteria for chronic endometritis (CE) have not been established due to differences in study design among researchers and a lack of typical clinical cases. Lipopolysaccharides (LPSs) have been reported to cause inflammation in the reproductive systems of several animals. This study aimed to elucidate the influence of LPS in the pathogenesis of CE in humans. We investigated whether LPS affected cytokine production and cell proliferation in the endometrium using in vivo and in vitro experiments. LPS concentrations were analyzed between control and CE patients using endometrial tissues. LPS administration stimulated the proliferation of EM-E6/E7 cells derived from human endometrial cells. High LPS concentrations were detected in CE patients. LPS concentration was found to correlate with IL-6 gene expression in the endometrium. Inflammation signaling evoked by LPS led to the onset of CE, since LPS stimulates inflammatory responses and cell cycles in the endometrium. We identified LPS and IL-6 as suitable candidate markers for the diagnosis of CE.


Subject(s)
Endometritis , Interleukin-6 , Lipopolysaccharides , Animals , Female , Humans , Endometritis/diagnosis , Endometritis/pathology , Endometrium/metabolism , Inflammation/metabolism , Interleukin-6/metabolism , Lipopolysaccharides/metabolism
2.
Gynecol Oncol ; 127(1): 172-4, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22750259

ABSTRACT

OBJECTIVE: Lafutidine, an antagonist of histamine H2-receptor, has gastroprotective activity associated with activation of capsaicin-mediated sensory nerves. The objective of this study was to investigate the efficacy of lafutidine for the treatment of taxane-induced peripheral neuropathy in patients with gynecological malignancies. METHODS: Twenty patients with taxane-induced peripheral neuropathy during the treatment of gynecological malignancy were enrolled in this study. After obtaining their informed consent, lafutidine (20mg per day) was administered orally, the efficacy of which was assessed according to the Patient Neurotoxicity Questionnaire item 1. RESULTS: Significant, moderate, slight, and no effects were observed in four, five, five, and six patients, respectively. The efficacy including significant and moderate effect was observed in nine (45%) of the 20 patients (95% confidence interval, 25.8%-65.8%). No adverse effects due to lafutidine were observed. CONCLUSION: This pilot study supports the relatively high efficacy of lafutidine for the treatment of taxane-induced peripheral neuropathy. Further prospective studies are warranted.


Subject(s)
Acetamides/therapeutic use , Antineoplastic Agents/adverse effects , Bridged-Ring Compounds/adverse effects , Genital Neoplasms, Female/drug therapy , Histamine H2 Antagonists/therapeutic use , Peripheral Nervous System Diseases/chemically induced , Piperidines/therapeutic use , Pyridines/therapeutic use , Taxoids/adverse effects , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Bridged-Ring Compounds/therapeutic use , Female , Humans , Middle Aged , Peripheral Nervous System Diseases/drug therapy , Taxoids/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...